Key result
A cumulative profile of four polymorphisms in the ACE, angiotensinogen, and (pro)renin receptor genes was associated with a 2-3-fold stepwise increase in hypertension prevalence.
Why the study?
Are genetic variations in the RAAS and kallikrein-bradykinin pathways associated with hypertension and blood pressure response to ACE inhibitor therapy in patients with vascular disease and healthy individuals?
Observational (n=14,675)
Yes
Are genetic variations in the RAAS and kallikrein-bradykinin pathways associated with hypertension and blood pressure response to ACE inhibitor therapy in patients with vascular disease and healthy individuals?
Specific genetic polymorphisms in the RAAS pathway are associated with a stepwise increase in the prevalence of hypertension across vascular disease and healthy cohorts, though their effect on ACE inhibitor blood pressure response is minimal.
Answers are grounded in this paper and cite their sources.
May aid hypertension risk stratification; leaves open whether RAAS variants guide ACE inhibitor response in vascular disease.
AIMS: To investigate whether genetic variation in the renin-angiotensin-aldosterone system (RAAS) and kallikrein-bradykinin pathways is related to hypertension and blood pressure (BP) response to angiotensin-converting enzyme (ACE) inhibitor therapy in stable coronary artery disease (CAD) patients. METHODS AND RESULTS: In 8907 stable CAD patients from the EUROPA trial, 52 haplotype-tagging single-nucleotide polymorphisms (SNPs) in 12 candidate genes within the RAAS and kallikrein-bradykinin pathways were investigated for association with hypertension (defined as BP ≥160/95 mmHg or use of antihypertensives) and BP response to ACE inhibitors, during a 4-week run-in period. All analyses were adjusted for age, sex, body mass index and creatinine clearance and corrected for multiple testing. RESULTS: Hypertension was present in 28.3% of the patients (n = 2526); median BP reduction after perindopril was 10/4 mmHg. Four polymorphisms, located in the ACE (rs4291), angiotensinogen (rs5049) and (pro)renin receptor (rs2968915; rs5981008) genes were significantly associated with hypertension in two vascular disease populations of CAD (EUROPA) and cerebrovascular disease (PROGRESS; n = 3571). A cumulative profile demonstrated a stepwise increase in the prevalence of hypertension, mounting to a 2-3-fold increase (P for trend <0.001). Similar associations on hypertension were observed for angiotensinogen in a healthy population (n = 2197). In addition, genetic polymorphisms were identified that significantly modified the BP reduction by ACE inhibitor therapy; however, the observed BP differences were small and did not remain significant after permutation analysis. CONCLUSION: This large genetic association study identified genetic determinants of hypertension in three cohorts of patients with vascular disease and healthy individuals.
No takes yet. Share an insight, caveat, or question.
Brugts et al. (2010) conducted an observational in Hypertension and vascular disease (n=14,675). Genetic variation in the RAAS and kallikrein-bradykinin pathways vs. Absence of specific genetic polymorphisms was evaluated on Hypertension (BP ≥160/95 mmHg or use of antihypertensives) and BP response to ACE inhibitors (p=<0.001). A cumulative profile of four polymorphisms in the ACE, angiotensinogen, and (pro)renin receptor genes was associated with a 2-3-fold stepwise increase in hypertension prevalence.
Synapse has enriched 10 related papers. Consider them for comparative context: